Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy.

Petros  Grivas

Consulting or Advisory Role - 4D Pharma; Astellas Pharma; AstraZeneca; BostonGene; Bristol-Myers Squibb; Dyania Health; EMD Serono; Exelixis; Fresenius Kabi; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; Infinity Pharmaceuticals; Janssen; Lucence; Merck; Mirati Therapeutics; Pfizer; PureTech; QED Therapeutics; Regeneron; Roche; Seagen; Silverback Therapeutics; Urogen pharma

Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)

Damien  Pouessel

Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Ipsen; Ipsen; Ipsen; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Merck; Merck; Merck; Merck

Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Pfizer; Pfizer; Pfizer; Pfizer; Sanofi; Sanofi; Sanofi; Sanofi

Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc, Rahway, NJ USA (Inst); Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc, Rahway, NJ USA (Inst); Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc, Rahway, NJ USA (Inst); Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc, Rahway, NJ USA (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)

Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Pfizer; Pfizer; Pfizer; Pfizer

Chandler H.  Park

No Relationships to Disclose

Philippe  Barthelemy

Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; BMS; BMS; BMS; BMS; IPSEN; IPSEN; IPSEN; IPSEN; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Seagen; Seagen; Seagen; Seagen

Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; BMS; BMS; BMS; BMS; Eisai; Eisai; Eisai; Eisai; ipsen; ipsen; ipsen; ipsen; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Pfizer; Pfizer; Pfizer; Pfizer

Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; BMS; BMS; BMS; BMS; IPSEN; IPSEN; IPSEN; IPSEN; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; MSD; MSD; MSD; MSD; Pfizer; Pfizer; Pfizer; Pfizer

Manojkumar  Bupathi

Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Exelixis; Pfizer; Pfizer; Pfizer; Pfizer

Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis

Speakers' Bureau - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Pfizer; Pfizer; Pfizer; Pfizer

Daniel P.  Petrylak

Stock and Other Ownership Interests  - Bellicum Pharmaceuticals; TYME

Consulting or Advisory Role - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Exelixis; Exelixis; Exelixis; Exelixis; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Incyte; Incyte; Incyte; Incyte; Ipsen; Ipsen; Ipsen; Ipsen; Janssen; Janssen; Janssen; Janssen; Lilly; Lilly; Lilly; Lilly; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Pfizer; Pfizer; Pfizer; Pfizer; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Regeneron; Regeneron; Regeneron; Regeneron; Roche; Roche; Roche; Roche; Seagen; Seagen; Seagen; Seagen; Urogen pharma; Urogen pharma; Urogen pharma; Urogen pharma

Research Funding - Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Agensys (Inst); Agensys (Inst); Agensys (Inst); Agensys (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Replimune (Inst); Replimune (Inst); Replimune (Inst); Replimune (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)

Expert Testimony - Celgene; Celgene; Celgene; Celgene; sanofi; sanofi; sanofi; sanofi

Neeraj  Agarwal

Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AVEO; AVEO; AVEO; AVEO; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Calithera Biosciences; Calithera Biosciences; Calithera Biosciences; Calithera Biosciences; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Exelixis; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Genentech; Genentech; Genentech; Genentech; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Medivation/Astellas; Medivation/Astellas; Medivation/Astellas; Medivation/Astellas; MEI Pharma; MEI Pharma; MEI Pharma; MEI Pharma; Merck; Merck; Merck; Merck; Nektar; Nektar; Nektar; Nektar; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Seagen; Seagen; Seagen; Seagen

Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Arvinas (Inst); Arvinas (Inst); Arvinas (Inst); Arvinas (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Celldex (Inst); Celldex (Inst); Celldex (Inst); Celldex (Inst); crispr therapeutics (Inst); crispr therapeutics (Inst); crispr therapeutics (Inst); crispr therapeutics (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)

Sumati  Gupta

Stock and Other Ownership Interests  - Salarius Pharmaceuticals (I); Salarius Pharmaceuticals (I); Salarius Pharmaceuticals (I); Salarius Pharmaceuticals (I)

Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Daiichi Sankyo/Lilly (Inst); Daiichi Sankyo/Lilly (Inst); Daiichi Sankyo/Lilly (Inst); Daiichi Sankyo/Lilly (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Hoosier Cancer Research Network (Inst); Hoosier Cancer Research Network (Inst); Hoosier Cancer Research Network (Inst); Hoosier Cancer Research Network (Inst); Immunocore (Inst); Immunocore (Inst); Immunocore (Inst); Immunocore (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); LSK BioPharma (Inst); LSK BioPharma (Inst); LSK BioPharma (Inst); LSK BioPharma (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Rexahn Pharmaceuticals (Inst); Rexahn Pharmaceuticals (Inst); Rexahn Pharmaceuticals (Inst); Rexahn Pharmaceuticals (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Viralytics (Inst); Viralytics (Inst); Viralytics (Inst); Viralytics (Inst)

Travel, Accommodations, Expenses - QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics

Aude  Flechon

Honoraria - AAA HealthCare; AAA HealthCare; AAA HealthCare; AAA HealthCare; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; BMS; BMS; BMS; BMS; Ipsen; Ipsen; Ipsen; Ipsen; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; PFIZER; PFIZER; PFIZER; PFIZER; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis

Travel, Accommodations, Expenses - AAA HealthCare; AAA HealthCare; AAA HealthCare; AAA HealthCare; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; BMS; BMS; BMS; BMS; IPSEN; IPSEN; IPSEN; IPSEN; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Pfizer; Pfizer; Pfizer; Pfizer; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis

Chethan  Ramamurthy

Consulting or Advisory Role - Seagen; Seagen; Seagen; Seagen

Speakers' Bureau - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences

Nancy B.  Davis

Consulting or Advisory Role - Janssen Biotech; Janssen Biotech; Janssen Biotech; Janssen Biotech

Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst)

Alejandro  Recio-Boiles

No Relationships to Disclose

Cora N.  Sternberg

Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Bristol-Myers Squibb/Medarex; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Genzyme; Genzyme; Genzyme; Genzyme; Immunomedics; Immunomedics; Immunomedics; Immunomedics; IMPAC Medical Systems; IMPAC Medical Systems; IMPAC Medical Systems; IMPAC Medical Systems; Incyte; Incyte; Incyte; Incyte; Medscape; Medscape; Medscape; Medscape; Merck; Merck; Merck; Merck; MSD; MSD; MSD; MSD; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche; UroToday; UroToday; UroToday; UroToday

Astha  Bhatia

Employment - Bayer; Bayer; Bayer; Bayer; Bayer; Bayer; Bayer; Bayer; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation

Stock and Other Ownership Interests  - Bayer; Bayer; Bayer; Bayer; Bayer; Bayer; Bayer; Bayer; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation

Cabilia  Pichardo

Employment - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences

Mitch  Sierecki

Employment - Bayer; Bayer; Bayer; Bayer; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences

Stock and Other Ownership Interests  - Bayer; Bayer; Bayer; Bayer; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences

Julia  Tonelli

No Relationships to Disclose

Huafeng  Zhou

Employment - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences

Stock and Other Ownership Interests  - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences

Scott T.  Tagawa

Consulting or Advisory Role - 4D Pharma; 4D Pharma; 4D Pharma; 4D Pharma; Abbvie; Abbvie; Abbvie; Abbvie; AIkido Pharma; AIkido Pharma; AIkido Pharma; AIkido Pharma; Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bayer; Bayer; Bayer; Bayer; Blue Earth Diagnostics; Blue Earth Diagnostics; Blue Earth Diagnostics; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clarity Pharmaceuticals; Clarity Pharmaceuticals; Clarity Pharmaceuticals; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Convergent Therapeutics; Convergent Therapeutics; Convergent Therapeutics; Convergent Therapeutics; Dendreon; Dendreon; Dendreon; Dendreon; Endocyte; Endocyte; Endocyte; Endocyte; Genentech; Genentech; Genentech; Genentech; Genomic Health; Genomic Health; Genomic Health; Genomic Health; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Immunomedics; Immunomedics; Immunomedics; Immunomedics; Janssen; Janssen; Janssen; Janssen; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Medivation; Medivation; Medivation; Medivation; Myovant Sciences; Myovant Sciences; Myovant Sciences; Myovant Sciences; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; POINT Biopharma; POINT Biopharma; POINT Biopharma; POINT Biopharma; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics; Sanofi; Sanofi; Sanofi; Sanofi; Seagen; Seagen; Seagen; Seagen; Telix Pharmaceuticals; Telix Pharmaceuticals; Telix Pharmaceuticals; Telix Pharmaceuticals; Tolmar; Tolmar; Tolmar; Tolmar

Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AVEO (Inst); AVEO (Inst); AVEO (Inst); AVEO (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Dendreon (Inst); Dendreon (Inst); Dendreon (Inst); Dendreon (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Millennium (Inst); Millennium (Inst); Millennium (Inst); Millennium (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Rexahn Pharmaceuticals (Inst); Rexahn Pharmaceuticals (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Stem CentRx (Inst); Stem CentRx (Inst); Stem CentRx (Inst); Stem CentRx (Inst)

Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead; Patent Royalty from Immunomedics / Gilead; Patent Royalty from Immunomedics / Gilead; Patent Royalty from Immunomedics / Gilead

Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Immunomedics; Immunomedics; Immunomedics; Immunomedics; Sanofi; Sanofi; Sanofi; Sanofi

(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; ATLAB Pharma; ATLAB Pharma; ATLAB Pharma; Phosplatin Therapeutics; Phosplatin Therapeutics; Phosplatin Therapeutics; Phosplatin Therapeutics

Yohann  Loriot

Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Immunomedics; Immunomedics; Immunomedics; Immunomedics; Janssen; Janssen; Janssen; Janssen; Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Loxo/Lilly; Loxo/Lilly; Loxo/Lilly; Loxo/Lilly; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Roche; Roche; Roche; Roche; Seagen; Seagen; Seagen; Seagen; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical

Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Basilea (Inst); Basilea (Inst); Basilea (Inst); Basilea (Inst); BMS (Inst); BMS (Inst); BMS (Inst); BMS (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)

Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Roche; Roche; Roche; Roche; Seagen; Seagen; Seagen; Seagen